Needham Lifts Price Target on Dyax (DYAX) to $8 Dec 2, 2009 09:56AM

Needham & Co lifted theier price targete on Dyax Corp. (Nasdaq: DYAX) to $8 from $6, following FDA approval of KALBITOR for the treatment of acute attacks of hereditary angioedema in patients 16 ...


Needham & Co Upgrades Dyax (DYAX) to Buy Jul 22, 2009 02:28PM

Intra-day Needham & Co upgrades Dyax (Nasdaq: DYAX) from Hold to Buy with a $6 price target, after the company reviewed 2Q09 progress and expectations for 2009 this ...


Needham & Co Downgrades Dyax Corp. (DYAX) to Hold Feb 5, 2009 09:51AM

Needham & Co downgrades Dyax Corp. (Nasdaq: DYAX) to Hold.

Needham analyst says, "Yesterday, the Pulmonary-Allergy Drugs Advisory Committee (PADAC) met to discuss the BLA for Dyax's KALBITOR ecallantide for the treatment of acute ...